← Leaderboards
Lawrence B Blyn
Isis Pharmaceuticals, Inc.
$5,462,112
Attributed
$5,462,112
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.9M · FY2005–09$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$5,462,112 · 2
By mechanism
UC1$4,873,632 · 1
R41$588,480 · 1
Top collaborators
No co-investigators on record.
Most similar at Isis Pharmaceuticals, Inc.
Same institution · by research overlap
- David J Ecker$0
- Eric E Swayze$2,149,351
Others in their field
Top investigators on “Detection”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Francis L Halzen · University Of Wisconsin-Madison$243,423,219
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Richard A Gibbs · Baylor College Of Medicine$209,716,260
- Richard K. Wilson · Washington University$206,265,868
- Craig B Thompson · Sloan-Kettering Inst Can Research$156,512,301
Research focus
DetectionDiagnosis Design /EvaluationAnti-Hepatitis CAmericanAntiviral TherapyAnalytical MethodBase SequenceBiodefenseBioinformaticsAntiviral AgentsBioterrorism /Chemical WarfareBusinessesCalibrationBaseCirrhosisClassificationClinical TrialsComparativeComputer Program /SoftwareComputer System Design /EvaluationBiosensorConsensusCostDiagnosis Quality /Standard
Grant awards (4)
HCV Genotyping and Drug Resistance Testing by ESI/MS$297,945
R41 · FY2009 · AI · contact PI
HCV Genotyping and Drug Resistance Testing by ESI/MS$290,535
R41 · FY2008 · AI · contact PI
Pathogen diagnostic products--Biodefense developments$4,649,863
UC1 · FY2005 · AI
Pathogen diagnostic products--Biodefense developments$223,769
UC1 · FY2005 · AI